Adalimumab biosimilar ABP 501 is equally effective and safe in long-term management of inflammatory bowel diseases patients when used as first biologic treatment or as replace of the ADA originator for a non-medical reason

• Published in: Frontiers in gastroenterology (Lausanne, Switzerland) Switzerland), 2023-10, Vol.2
• Main Authors: Mocci, Giammarco, Cingolani, Arianna, Orrù, Giorgia, Felice, Carla, Onidi, Francesca Maria, Lombardi, Gianmarco, Checchin, Davide, Colucci, Raffaele, Grossi, Laurino, Ferronato, Antonio, Rocchi, Chiara, Ascolani, Marta, Satta, Paolo Usai, Fanini, Lucia, Pilati, Stefano, Tursi, Antonio
• Format: Article
• Language: English
• Subjects: ABP 501; adalimumab; biosimilar; Crohn’s disease; ulcerative colitis
• ISSN: 2813-1169; 2813-1169
• DOI: 10.3389/fgstr.2023.1218228

ObjectiveBiosimilars represent a new opportunity for inflammatory bowel disease (IBD) treatment and economic sustainability of therapies. This study aimed to evaluate the efficacy and long-term safety of the adalimumab biosimilar ABP 501 in biologic-naïve vs. biologic-switched IBD patients.MethodsA retrospective observational study was conducted using a database of patients with IBD treated with ABP 501, biologic-naïve or switched from the original, at eight IBD centers. We included adult patients with at least one year of follow-up. The primary objective of this study was to assess the efficacy (persistence) and safety (adverse event rate) of ABP 501 therapy.ResultsA total of 118 patients with IBD were included in the analysis: 84 patients with Crohn’s disease (CD) (39 women, 45 men, mean age 40.4 ± 14.3 years; 33% biologic-naïve) and 34 patients with ulcerative Colitis (UC) (16 women, 18 men, mean age 38.9 ± 14.9 years; 61.8% biologic-naïve). Regarding the primary endpoint, no difference was observed in the efficacy between biologic-naïve patients and patients with Adalimumab (ADA) originator replacement for non-medical reasons in terms of long-term persistence. However, ABP 501 showed a higher percentage of sustained clinical remission at 2 years in patients with CD (64 patients, 77%) than in those with UC (15 patients, 45.5%; p=0.00091). Nine patients (six with CD and three with UC) experienced adverse events that led to drug discontinuation in three.ConclusionsAPB 501 showed a good safety and efficacy profile in maintaining clinical response at 2 years in patients with IBD, both as a treatment-naïve and as a replacement for ADA originator for non-medical reasons.